G-207 is under clinical development by Treovir and currently in Phase I for Ependymoma. According to GlobalData, Phase I drugs for Ependymoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the G-207 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

G-207 overview

G-207 is under development for high-grade glioma in children, medulloblastoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid/rhabdoid tumor and germ cell tumor, supratentorial brain tumor, gliosarcoma, glioblastoma multiforme, giant cell glioblastoma, midline diffuse glioma and anaplastic astrocytoma. The drug candidate is administered by intracerebral and intratumor routes. G207 is a modified herpes simplex type 1 virus (HSV) that has been genetically engineered to replicate aggressively in cancer cells to kill them while sparing normal cells. The drug candidate is based on HSV technology (now known as adeno-associated virus-like particles technology).

It was also under development for recurrent glioblastoma multiforme.

Treovir overview

Treovir is a healthcare company that develops and commercialises G207 for recurrent glioblastoma in children. The company is headquartered in Bala Cynwyd, Pennsylvania, the US.

For a complete picture of G-207’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.